Peter Wirth
InvestorSenior Advisor at Quan Capital
About
Peter Wirth has served as Chairman of the board of Syros Pharmaceuticals since 2017 and previously chaired FORMA Therapeutics Holdings LLC until its 2022 acquisition by Novo Nordisk, as well as serving as a director of Zai Lab Limited. He co-founded Lysosomal Therapeutics and held senior executive roles at Genzyme Corporation, including Executive Vice President of Legal and Corporate Development and Chief Risk Officer, and spent over 20 years as a partner and head of the biotechnology practice at Palmer & Dodge LLP. He holds a J.D. from Harvard Law School and a B.A. in Political Science from the University of Wisconsin at Madison.
Invests in
Biotech
Investments
Board seats
FORMA Therapeutics Holdings LLCSyros PharmaceuticalsZai Lab Limited
Per the firm's website.
Colleagues at Quan Capital
Frequently asked questions
- Who is Peter Wirth?
- Peter Wirth has served as Chairman of the board of Syros Pharmaceuticals since 2017 and previously chaired FORMA Therapeutics Holdings LLC until its 2022 acquisition by Novo Nordisk, as well as serving as a director of Zai Lab Limited. He co-founded Lysosomal Therapeutics and held senior executive roles at Genzyme Corporation, including Executive Vice President of Legal and Corporate Development and Chief Risk Officer, and spent over 20 years as a partner and head of the biotechnology practice at Palmer & Dodge LLP. He holds a J.D. from Harvard Law School and a B.A. in Political Science from the University of Wisconsin at Madison.
- Where does Peter Wirth work?
- Peter Wirth is Senior Advisor at Quan Capital.
- What does Peter Wirth invest in?
- Peter Wirth invests in Biotech.
- What boards does Peter Wirth sit on?
- Peter Wirth holds tracked board seats at FORMA Therapeutics Holdings LLC, Syros Pharmaceuticals, Zai Lab Limited.